CN112996816B - 抗糖-muc1抗体及其用途 - Google Patents

抗糖-muc1抗体及其用途

Info

Publication number
CN112996816B
CN112996816B CN201980056864.6A CN201980056864A CN112996816B CN 112996816 B CN112996816 B CN 112996816B CN 201980056864 A CN201980056864 A CN 201980056864A CN 112996816 B CN112996816 B CN 112996816B
Authority
CN
China
Prior art keywords
seq
antibody
muc
nos
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980056864.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996816A (zh
Inventor
T.怀特
H.万达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Go Medical Co ltd
Original Assignee
Go Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Medical Co ltd filed Critical Go Medical Co ltd
Publication of CN112996816A publication Critical patent/CN112996816A/zh
Application granted granted Critical
Publication of CN112996816B publication Critical patent/CN112996816B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201980056864.6A 2018-06-29 2019-06-28 抗糖-muc1抗体及其用途 Active CN112996816B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862691887P 2018-06-29 2018-06-29
US62/691,887 2018-06-29
US201962802865P 2019-02-08 2019-02-08
US62/802,865 2019-02-08
PCT/US2019/039883 WO2020006449A1 (en) 2018-06-29 2019-06-28 Anti-glyc0-muc1 antibodies and their uses

Publications (2)

Publication Number Publication Date
CN112996816A CN112996816A (zh) 2021-06-18
CN112996816B true CN112996816B (zh) 2025-12-02

Family

ID=68987626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056864.6A Active CN112996816B (zh) 2018-06-29 2019-06-28 抗糖-muc1抗体及其用途

Country Status (5)

Country Link
US (2) US12269892B2 (https=)
EP (1) EP3814384A4 (https=)
JP (1) JP7541930B2 (https=)
CN (1) CN112996816B (https=)
WO (1) WO2020006449A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114860A1 (en) * 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
BR112023001739A2 (pt) * 2020-07-31 2023-02-28 Scherer Technologies Llc R P Anticorpo específico para mucina-1 e métodos de uso do mesmo
AU2022420709A1 (en) * 2021-12-21 2024-08-01 Merus B.V. Binding domains against cancer-associated muc1
WO2025114381A1 (en) * 2023-11-27 2025-06-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Muc1 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012309A1 (en) * 2009-07-31 2011-02-03 Glycotope Gmbh Muc1 antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE123066T1 (de) 1988-03-11 1995-06-15 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden- trägerkonjugaten.
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001075110A2 (en) 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
US7338932B2 (en) 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1141142C (zh) * 2001-02-08 2004-03-10 北京迪威华宇生物技术有限公司 人乳腺癌muc-1抗原基因工程疫苗
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP2083868A2 (en) 2006-10-04 2009-08-05 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
TWI405770B (zh) * 2007-07-31 2013-08-21 Glytech Inc Production of peptides
JP5532401B2 (ja) 2007-12-05 2014-06-25 協和発酵キリン株式会社 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5773352B2 (ja) 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
EP2565268A4 (en) 2010-04-28 2013-10-09 Shionogi & Co NEW MUC1 ANTIBODY
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US20170145108A1 (en) 2014-02-05 2017-05-25 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
AU2015254257B2 (en) 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
US20170129962A1 (en) 2015-10-02 2017-05-11 Hoffmann-La Roche Inc. Multispecific antibodies
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
AU2018241781A1 (en) 2017-03-29 2019-07-18 Glycotope Gmbh Multispecific antibody constructs binding to MUC1 and CD3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012309A1 (en) * 2009-07-31 2011-02-03 Glycotope Gmbh Muc1 antibodies

Also Published As

Publication number Publication date
US12269892B2 (en) 2025-04-08
US20210269552A1 (en) 2021-09-02
WO2020006449A1 (en) 2020-01-02
EP3814384A4 (en) 2022-03-23
US20250304716A1 (en) 2025-10-02
JP7541930B2 (ja) 2024-08-29
EP3814384A1 (en) 2021-05-05
JP2021529524A (ja) 2021-11-04
CN112996816A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
JP7849340B2 (ja) 抗グリコｍｕｃ１抗体およびその使用
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
KR20240101546A (ko) 항-글리코-lamp1 항체 및 그의 용도
KR20240109604A (ko) 항-글리코-cMET 항체 및 그의 용도
US20250101126A1 (en) Anti-glyco-muc4 antibodies and their uses
US20250326855A1 (en) Anti-glyco-cd44 antibodies and their uses
CN118354788A (zh) 抗糖-muc4抗体及其用途
HK40114974A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant